Genprex Roche Diagnostics TROP2 Collaboration | Lucid Diligence Brief
Genprex and Roche Diagnostics begin TROP2 assay validation to support…
Nucleai-University of Glasgow Partnership Expands Spatial AI Platform | Lucid Diligence Brief
Nucleai broadened its University of Glasgow collaboration to expand academic…
Public Health Strategic Roundup | June 11–July 15, 2026
Key Strategic Developments Shaping Public Health Coverage: June 11–July 15,…
Lucid Diligence Brief: Genhouse Bio and Gilead in GH31 synthetic-lethal oncology $1.5B deal
Lucid Diligence Brief: Genhouse Bio and Gilead in GH31 synthetic-lethal…
Lucid Diligence Brief: AstraZeneca to acquire Modella AI
Lucid Diligence Brief: AstraZeneca to acquire Modella AI Professional audiences…
ESMO Immuno-Oncology 2025 Preview: Key Highlights to Watch
ESMO Immuno-Oncology 2025 at a glance Get ready for ESMO Immuno-Oncology…
Lucid Diligence Brief: General Proximity and Daiichi Sankyo multi-target induced-proximity oncology deal
Lucid Diligence Brief: General Proximity and Daiichi Sankyo multi-target…
Neuroscience Weekly News - October 8th 2025
🧠 This Week in Neuroscience: China’s Nerivio Nod, Ocrevus in Pediatric MS,…
ECTRIMS 2025 Preview: Key Multiple Sclerosis Highlights to Watch
ECTRIMS 2025 at a glance Ahead of ECTRIMS 2025 in Barcelona, see what to…
ESMO GI 2025 Preview: Key Gastrointestinal Oncology Highlights to Watch
ESMO GI 2025 at a glance Get ready for ESMO GI 2025 with LucidQuest’s…
ASCO 2025 Preview: Key Oncology Highlights to Watch
ASCO 2025 at a glance Prepare for ASCO 2025 with LucidQuest’s concise…
ASGCT 2025 PREVIEW: Key Cell and Gene Therapy Highlights to Watch
ASGCT 2025 at a glance Count down to ASGCT 2025 with LucidQuest’s brief…